Latest news Image: Bru-nO/PixabayEASL 2020: NAFLDFatty liver disease affects one in four in Europe, study estimates. Professor Heiner Wedemeyer of Essen University Hospital.EASL 2020: Hepatitis DBulevirtide shows promise as maintenance therapy for hepatitis D. Rohit Loomba presenting to EASL 2020.EASL 2020: Experimental treatments for NASH/NAFLDExperimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits. infohep news Experimental treatments for NASH/NAFLD Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes Liz Highleyman / 26 October 2020 Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ... Experimental treatments for NASH/NAFLD Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits Liz Highleyman / 20 October 2020 Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ... View all infohep news Editors' picks from other sources Increased Coffee Intake May Lower Risk of Liver-Related Death HepMag / 27 October 2020 Hepatitis C eradication in Korea 10 years behind WHO target Korea Biomedical News / 13 October 2020 Why Don’t We Have a Hepatitis C Vaccine Yet? Inside Science / 13 October 2020 View all news from other sources Conference news More conference news Noticeboard ILC 2016 webinar: watch again More noticeboard posts Email updates Sign up for our monthly bulletins Sign up today Other pages in this section Latest news All the news Conference news Noticeboard Email bulletins News feeds